Single-Agent Brentuximab Vedotin in Patients with Relapsed/Refractory Mycosis Fungoides


Single-Agent Brentuximab Vedotin in Patients with Relapsed/Refractory Mycosis Fungoides
Slides from a presentation at ASH 2012 and transcribed comments from recent interviews with Bruce D Cheson, MD (1/14/13) and Steven M Horwitz, MD (3/14/13)

Krathen M et al. Brentuximab vedotin demonstrates significant clinical activity in relapsed or refractory mycosis fungoides with variable CD30 expression. Proc ASH 2012;Abstract 797.

Dr Cheson is Professor of Medicine, Deputy Chief of the Division of Hematology-Oncology and Head of Hematology at the Georgetown University Hospital Lombardi Comprehensive Cancer Center in Washington, DC.

Dr Horwitz is Assistant Attending in the Division of Hematologic Oncology’s Lymphoma Service at Memorial Sloan-Kettering Cancer Center in New York, New York.